MedComm

metrics 2024

Connecting Researchers for Global Impact

Introduction

MedComm is a distinguished Open Access journal published by Wiley, located in the United States. Since its inception in 2020, it has rapidly established itself as a leading platform for cutting-edge research in the fields of Biochemistry, Cell Biology, Drug Discovery, Genetics, Immunology and Allergy, and Oncology, achieving a prestigious Q1 category ranking across multiple disciplines in 2023. MedComm is committed to providing a rigorous and transparent peer-review process, ensuring the publication of high-quality articles that advance the frontiers of medical science. With its remarkable Scopus ranking, the journal serves as an invaluable resource for researchers, professionals, and students looking to stay abreast of important developments in the life sciences. The open access model facilitates widespread dissemination of scholarly work, fostering collaboration and innovation within the global scientific community. Researchers interested in submitting their work or exploring the latest findings are encouraged to engage with this pivotal journal during the converged years from 2020 to 2024.

Metrics 2024

SCIMAGO Journal Rank-
Journal Impact Factor10.70
Journal Impact Factor (5 years)9.70
H-Index-
Journal IF Without Self10.70
Eigen Factor0.00
Normal Eigen Factor0.53
Influence1.99
Immediacy Index1.60
Cited Half Life1.90
Citing Half Life5.10
JCI1.67
Total Documents-
WOS Total Citations1737
SCIMAGO Total Citations-
SCIMAGO SELF Citations-
Scopus Journal Rank-
Cites / Document (2 Years)-
Cites / Document (3 Years)-
Cites / Document (4 Years)-

Metrics History

Rank 2024

IF (Web Of Science)

MEDICINE, RESEARCH & EXPERIMENTAL
Rank 11/189
Percentile 94.40
Quartile Q1

JCI (Web Of Science)

MEDICINE, RESEARCH & EXPERIMENTAL
Rank 17/189
Percentile 91.01
Quartile Q1

Quartile History

Similar Journals

Cell Reports Medicine

Empowering researchers with accessible, high-impact findings.
Publisher: CELL PRESSISSN: 2666-3791Frequency: 12 issues/year

Cell Reports Medicine, published by Cell Press, represents a pivotal advancement in the open access landscape of biomedical research since its inception in 2020. With a dedicated focus on the intersection of medicine, biochemistry, genetics, and molecular biology, this journal has quickly established itself as a key resource, earning a remarkable Q1 ranking in these fields. Based in the United States, Cell Reports Medicine boasts impressive metrics, ranking #25 out of 636 in General Medicine and #18 out of 221 in Biochemistry, underscoring its influence and reach within the scientific community, with a notable 96th and 92nd percentile respectively. As a fully open access journal, it fosters global dissemination of knowledge, ensuring that groundbreaking research is readily available to researchers, professionals, and students alike. The journal not only promotes high-quality research but also aims to bridge the gap between molecular discoveries and clinical applications, making it an essential addition to any academic library or researcher's toolkit.

BMC Molecular and Cell Biology

Illuminating the pathways of modern biological research.
Publisher: BMCISSN: Frequency: 1 issue/year

BMC Molecular and Cell Biology is a forward-thinking open-access journal published by BMC, specializing in the vital fields of molecular biology and cell biology. Since its inception in 2019, the journal has carved a niche for itself, ranking in the Q3 quartile in both Cell Biology and Molecular Biology categories as of 2023. With an ISSN of N/A and an E-ISSN of 2661-8850, the journal provides a platform for groundbreaking research, high-quality reviews, and innovative methodologies. Situated in the United Kingdom, BMC Molecular and Cell Biology promotes a diverse range of studies, addressing fundamental questions in biology that resonate with both experts and new researchers alike. The journal's commitment to open access ensures that valuable findings are readily available to the global scientific community, fostering collaboration and knowledge-sharing across disciplines. Researchers aiming to contribute to the field of cell and molecular biology will find this journal an indispensable resource for both publishing and staying informed on the latest advances.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Innovating Research on the Molecular Basis of Disease
Publisher: ELSEVIERISSN: 0925-4439Frequency: 12 issues/year

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, published by Elsevier, is a pivotal journal in the fields of Molecular Biology and Molecular Medicine, recognized for its high impact factor and robust ranking within Scopus categories, holding prestigious quartiles in Q1 for both disciplines as of 2023. With ISSN 0925-4439 and E-ISSN 1879-260X, this journal fosters cutting-edge research from 1990 to 2025, addressing the critical molecular mechanisms underlying human diseases. Its wide-ranging scope includes original research articles, reviews, and advanced theoretical insights, serving as an essential resource for researchers, clinicians, and students alike. The journal is based in the Netherlands, at RADARWEG 29, 1043 NX AMSTERDAM, and while it does not currently offer an open-access option, it continues to maintain a strong presence in the scientific community, enhancing our understanding of molecular processes in health and disease.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Empowering Researchers with Open Access Knowledge
Publisher: WILEYISSN: 1582-1838Frequency: 12 issues/year

Journal of Cellular and Molecular Medicine, published by Wiley, stands at the forefront of research excellence in the fields of cell biology and molecular medicine. With an impressive impact factor reflected in its 2023 Q2 category ranking for both Cell Biology and Molecular Medicine, this journal provides a vital platform for researchers and professionals alike, fostering innovative findings and groundbreaking discoveries since its inception in 2000. Maintaining an open access policy since 2012, the journal ensures that knowledge is freely disseminated, promoting collaboration and progress across the scientific community. With robust rankings in the Scopus database, including a position within the top 85th percentile in Molecular Medicine, the journal remains committed to advancing understanding of cellular functions and their implications in health and disease. Researchers, professionals, and students will find a treasure of high-quality articles and reviews that not only catalyze academic dialogue but also contribute significantly to practical applications in the life sciences.

Molecular Biomedicine

Exploring the Intersection of Biology and Medicine
Publisher: SPRINGERNATUREISSN: Frequency: 1 issue/year

Molecular Biomedicine is a prestigious peer-reviewed journal published by SpringerNature, dedicated to advancing the fields of molecular biology and molecular medicine. With a commendable Q1 ranking in both categories for 2023, this journal stands out for its rigorous exploration of the biochemical processes underlying health and disease. Operating out of Germany, Molecular Biomedicine aims to provide comprehensive insights into cutting-edge research, facilitating interdisciplinary collaboration among researchers, healthcare professionals, and students alike. The journal's impact is reflected in its Scopus rankings, placing it in the upper echelons of the fields of biochemistry, genetics, and molecular biology. As an open access platform, it commits to disseminating knowledge widely, ensuring that pivotal discoveries are accessible to all. Researchers looking to publish in a dynamic environment that prioritizes innovation and application in the biomedical sciences will find Molecular Biomedicine an ideal outlet for their work.

JOURNAL OF GENE MEDICINE

Elevating Standards in Gene Medicine Research
Publisher: WILEYISSN: 1099-498XFrequency: 12 issues/year

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

Journal of Translational Medicine

Pioneering the Path from Lab to Life.
Publisher: BMCISSN: Frequency: 1 issue/year

Journal of Translational Medicine, published by BMC in the United Kingdom, stands at the forefront of biomedical research, bridging the gap between laboratory discoveries and clinical applications. Established in 2003 as an Open Access journal, it has garnered significant recognition, achieving a Q1 quartile ranking in both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023. With an impressive Scopus rank of 38 out of 636 in General Medicine and 33 out of 221 in General Biochemistry, Genetics and Molecular Biology, the journal is committed to disseminating high-quality, peer-reviewed research that impacts healthcare and informs clinical practices. By facilitating free access to groundbreaking studies, the Journal of Translational Medicine aims to enhance collaboration among researchers, professionals, and students in the scientific community, fostering advancements in translational research well into the future.

EXPERIMENTAL AND MOLECULAR PATHOLOGY

Leading the way in molecular pathology research.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCEISSN: 0014-4800Frequency: 6 issues/year

EXPERIMENTAL AND MOLECULAR PATHOLOGY, a distinguished journal published by Academic Press Inc Elsevier Science, is recognized for its significant contributions to the fields of pathology, clinical biochemistry, and molecular biology. With an ISSN of 0014-4800 and an E-ISSN of 1096-0945, this journal provides a platform for the dissemination of high-quality research articles, reviews, and experimental studies that deepen our understanding of disease mechanisms and diagnostic pathways. Since its inception in 1962 and through its converged publication years, the journal has consistently maintained a solid impact in the academic community, achieving high Scopus rankings—ranked #15 in the field of Pathology and Forensic Medicine and #22 in Clinical Biochemistry, showcasing a commendable percentile standing of 93rd and 81st respectively in 2023. The journal is accessible through various academic libraries and institutional subscriptions, making it an essential resource for researchers, professionals, and students committed to advancing knowledge in these critical areas. With a categorization that includes Q1 rankings in Pathology and Forensic Medicine, EXPERIMENTAL AND MOLECULAR PATHOLOGY stands as a prominent venue for pioneering scientific inquiry and collaborative advancement in molecular diagnostics and therapeutic strategies.

MOLECULAR CANCER RESEARCH

Connecting Researchers to the Future of Cancer Care
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1541-7786Frequency: 12 issues/year

MOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.

BioImpacts

Connecting researchers to vital insights in health and disease.
Publisher: TABRIZ UNIV MEDICAL SCIENCES & HEALTH SERVICESISSN: 2228-5652Frequency: 4 issues/year

BioImpacts, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, is a prominent platform dedicated to advancing the fields of Biochemistry, Genetics, Molecular Biology, Medicine, and Pharmaceutical Science. Established in 2011, this Open Access journal ensures that vital research findings are freely accessible to the global academic community. With an impressive presence in the Scopus database, BioImpacts currently holds a Q2 quartile ranking in its respective categories, reflecting its contribution to scientific discourse and its importance as a critical resource for researchers and practitioners alike. The journal's dynamic scope encompasses a wide range of topics, highlighting innovative research that addresses contemporary challenges in health and disease. Operating out of Tabriz, Iran, BioImpacts is committed to fostering interdisciplinary collaboration and knowledge dissemination through their dedicated publication efforts, which span from 2011 to 2024. Researchers, professionals, and students are encouraged to explore the rich content and cutting-edge studies presented in this journal, making it an indispensable resource in the scientific community.